As an internationally recognized center for research and clinical care of patients with blood cancers, who conduct more clinical research studies than our regional peers, we believe in the importance of patient education. To this end we have created a Targeted Therapy Approval subsection for our websites Clinical Trials page.
This page will be updated with information about the newest, next generation of targeted therapies as they receive FDA Breakthrough Therapy Designation, and FDA approval. It is intended as an educational resource.
If you have any questions please contact Robert Birchard at rob2052@med.cornell.edu or 212-746-2919.
New Developments in Lymphoma 